#78 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians can now provide evidence-based reassurance to male patients concerned that cannabis use will impair their testosterone levels or fertility, potentially reducing unnecessary anxiety and improving patient counseling discussions. This finding is particularly relevant for young men considering or currently using cannabis, as prior uncertainty about hormonal effects may have influenced clinical recommendations or patient decision-making around use. Understanding that cannabis does not lower testosterone allows clinicians to focus reproductive health counseling on other modifiable risk factors with stronger evidence bases.
A recent study challenges the long-standing clinical concern that cannabis use suppresses testosterone levels in young men, finding no significant association between cannabis consumption and reduced testosterone in this population. This finding is clinically relevant given the widespread patient concern and provider counseling about cannabis-related hypogonadism, which has influenced treatment decisions and patient education in primary care and reproductive medicine. The study suggests that previous observational data linking cannabis to lower testosterone may have been confounded by other lifestyle factors or may not apply uniformly across all users. Clinicians should consider updating their risk-benefit discussions with male patients about cannabis use, particularly regarding fertility and sexual health concerns that have been based partly on presumed testosterone suppression. However, providers should note this represents one study and should continue monitoring emerging evidence on cannabis and endocrine function across diverse populations. For practical purposes, clinicians can reassure appropriately selected male patients that cannabis use alone may not be a direct cause of testosterone deficiency, though individualized assessment of other risk factors remains important.
“After two decades of clinical practice, I’ve watched patients avoid cannabis based on testosterone fears that the evidence simply doesn’t support, and this study reinforces what we’re increasingly seeing in the literature: the risk narrative around cannabis and male hormones has been overstated. What actually matters for my patients is honest counseling about real dose-dependent effects like acute impairment and respiratory risk, not chasing phantom endocrine problems that don’t materialize in rigorous research.”
💊 A recent study suggesting that cannabis use does not significantly lower testosterone in young men challenges long-standing clinical assumptions, though healthcare providers should interpret this finding cautiously given the heterogeneity of cannabis products, dosing patterns, and individual metabolic variation in clinical populations. The study’s cross-sectional design and focus on a specific demographic (young men) limit generalizability to older patients, chronic heavy users, or those with underlying endocrine conditions who may exhibit different responses. Important confounders such as frequency and duration of use, route of administration, cannabinoid ratios (THC versus CBD), and concurrent substance use or lifestyle factors were not fully characterized in available summaries, making it difficult to translate results directly to diverse patient populations. Clinicians counseling patients about cannabis and reproductive health should acknowledge this emerging evidence while maintaining awareness that long-term fertility and endocrine effects remain incompletely understood. When discussing cannabis with patients of reproductive age
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
